Health and Healthcare

The Generic Boniva Opportunity (RHHBY, MYL)

The Food and Drug Administration approval of the first generic versions of osteoporosis drug Boniva won’t be the end of Roche Holding AG (OTC: RHHBY) for its marketing of Boniva in the United States.  It will however help out smaller generic players like Apotex, Orchid, and Mylan Inc. (NASDAQ: MYL).

What makes Boniva unique in the osteoporosis market other than that Sally Fields was the ad woman is that it is a once per month tablet marketed to prevent osteoporosis in women after menopause. The osteoporosis drug aims to help increase bone mass to reduce the risks associated with weak bones and spinal fractures in women.

Apotex previously agreed not to sell the drug until the patent rulings were out, so the FDA allowance for generics will allow generics to begin selling.   There is an interesting set of figures.  At least 5 million patients are on one of the drugs under the class called “bisphosphonate therapy” which Boniva is one of several in that class.  Drugs.com noted that the total size of the osteoporosis market is $18 billion in the United States.

Mylan shares are down slightly on the day.  What portion of this generic market it can capture is still an unknown.

JON C. OGG

Credit Card Companies Are Doing Something Nuts

Credit card companies are at war. The biggest issuers are handing out free rewards and benefits to win the best customers.

It’s possible to find cards paying unlimited 1.5%, 2%, and even more today. That’s free money for qualified borrowers, and the type of thing that would be crazy to pass up. Those rewards can add up to thousands of dollars every year in free money, and include other benefits as well.

We’ve assembled some of the best credit cards for users today.  Don’t miss these offers because they won’t be this good forever.

 

Flywheel Publishing has partnered with CardRatings for our coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.

AI Portfolio

Discover Our Top AI Stocks

Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.

You can follow him investing $500,000 of his own money on our top AI stocks for free.